Royal Philips Q1 Earnings Forecast Dampened by Tariffs and China Sales
RBC Capital Markets analysts predict that Royal Philips will report first-quarter results next month with sales growth and profitability slightly below consensus estimates. The Dutch medical-technology firm faces incremental tariff headwinds, a longer lag in converting diagnosis-and-treatment orders to revenue, and more normalized growth for personal-health products in China. Consequently, RBC forecasts like-for-like sales growth of 3.1% (vs. 3.3% consensus) and an adjusted Ebita margin of 8.2% (vs. 8.3% consensus). Despite these cautious outlooks, Philips shares rose 4.3% following the news. This analysis is part of the Wall Street Journal's Health Care Roundup Market Talk series.
Wire timeline
Royal Philips Q1 Earnings Forecast Dampened by Tariffs and China Sales
RBC Capital Markets analysts predict that Royal Philips will report first-quarter results next month with sales growth and profitability slightly below consensus estimates. The Dutch medical-technology firm faces incremental tariff headwinds, a longer lag in converting diagnosis-and-treatment orders to revenue, and more normalized growth for personal-health products in China. Consequently, RBC forecasts like-for-like sales growth of 3.1% (vs. 3.3% consensus) and an adjusted Ebita margin of 8.2% (vs. 8.3% consensus). Despite these cautious outlooks, Philips shares rose 4.3% following the news. This analysis is part of the Wall Street Journal's Health Care Roundup Market Talk series.
WSJ.com: US Business